KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Accumulated Expenses (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Other Accumulated Expenses for 8 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 11.81% to $8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Dec 2025, up 11.81% year-over-year, with the annual reading at $8.9 million for FY2025, 11.81% up from the prior year.
  • Other Accumulated Expenses hit $8.9 million in Q4 2025 for Castle Biosciences, up from $8.9 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $8.9 million in Q4 2025 to a low of $2.0 million in Q1 2021.
  • Historically, Other Accumulated Expenses has averaged $6.4 million across 5 years, with a median of $7.0 million in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 223.84% in 2022 and later dropped 10.51% in 2023.
  • Year by year, Other Accumulated Expenses stood at $5.7 million in 2021, then dropped by 7.33% to $5.3 million in 2022, then skyrocketed by 39.05% to $7.3 million in 2023, then increased by 9.24% to $8.0 million in 2024, then grew by 11.81% to $8.9 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for CSTL at $8.9 million in Q4 2025, $8.9 million in Q3 2025, and $8.2 million in Q2 2025.